Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

PHAT

Phathom Pharmaceuticals Inc

Nov 27 • 04:00PM ET

8.97

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: NBIX BPMC AXSM BTAI ACAD VKTX MDGL PTGX RDUS XENE

| Held by: VTI VXF IWM SURI VTWO IWN VHT IBB DWAS SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.69	Insider Own	49.04%	Shs Outstand	57.97M	Perf Week	2.75%
Market Cap	613.35M	Forward P/E	-	EPS next Y	-4.10	Insider Trans	-0.15%	Shs Float	34.85M	Perf Month	-48.09%
Income	-339.44M	PEG	-	EPS next Q	-1.20	Inst Own	69.14%	Short Float	42.08%	Perf Quarter	-44.97%
Sales	26.27M	P/S	23.35	EPS this Y	-38.36%	Inst Trans	47.52%	Short Ratio	10.94	Perf Half Y	-11.97%
Book/sh	-2.74	P/B	-	EPS next Y	24.54%	ROA	-108.79%	Short Interest	14.66M	Perf Year	25.10%
Cash/sh	4.89	P/C	1.83	EPS next 5Y	-	ROE	-	52W Range	6.07 - 19.71	Perf YTD	-1.75%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-137.06%	ROI	-109.14%	52W High	-54.49%	Beta	0.57
Dividend TTM	-	Quick Ratio	5.68	Sales past 5Y	0.00%	Gross Margin	82.83%	52W Low	47.90%	ATR (14)	1.19
Dividend Ex-Date	-	Current Ratio	5.73	EPS Y/Y TTM	-48.61%	Oper. Margin	-1096.02%	RSI (14)	29.36	Volatility	8.36% 12.02%
Employees	452	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-1292.14%	Recom	1.25	Target Price	25.29
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-73.87%	Payout	-	Rel Volume	0.50	Prev Close	8.97
Sales Surprise	29.69%	EPS Surprise	10.12%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	1.34M	Price	8.97
SMA20	-27.99%	SMA50	-40.45%	SMA200	-26.69%	Trades		Volume	669,590	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-03-24	Initiated	Stifel	Buy	$24
Jan-05-24	Reiterated	Needham	Buy	$23 → $26
Aug-09-23	Initiated	H.C. Wainwright	Buy	$28
May-11-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-13-23	Initiated	Craig Hallum	Buy	$21
Oct-21-22	Initiated	Jefferies	Buy	$16
May-06-22	Downgrade	Evercore ISI	Outperform → In-line
May-12-21	Upgrade	Goldman	Sell → Neutral	$40 → $48
Feb-17-21	Initiated	BMO Capital Markets	Outperform	$63
Feb-02-21	Initiated	Guggenheim	Buy	$60
Jun-26-20	Downgrade	Goldman	Neutral → Sell	$34
Nov-20-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Needham	Buy	$40
Nov-19-19	Initiated	Jefferies	Buy	$32
Nov-19-19	Initiated	Goldman	Neutral	$32

Show Previous Ratings

Nov-19-24 12:00PM	Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know (Zacks) +5.40%
Nov-08-24 06:02AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -8.86%
Nov-07-24 09:20AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-24 07:21AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
08:00AM	Loading…
Nov-04-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-24 08:00AM	Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 (GlobeNewswire) +8.29%
Oct-27-24 12:00PM	Phathom Pharmaceuticals to Present VOQUEZNA Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting (GlobeNewswire)
Aug-29-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-19-24 08:00AM	Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Aug-08-24 09:20AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.70%
08:00AM	Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-30-24 08:00AM	Phathom Pharmaceuticals Announces VOQUEZNA (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients (GlobeNewswire)
Jul-29-24 07:59AM	Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024 (GlobeNewswire)
Jul-18-24 08:00AM	Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults (GlobeNewswire) -7.68%
07:00AM	Loading…
Jun-09-24 07:00AM	Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now (InvestorPlace)
Jun-07-24 06:17AM	Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze (InvestorPlace) +9.50%
May-28-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-15-24 08:00AM	Phathom Pharmaceuticals to Present VOQUEZNA (vonoprazan) Data at DDW 2024 Annual Meeting (GlobeNewswire)
May-13-24 11:02AM	Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 08:00AM	The 3 Best Healthcare Stocks to Buy in May 2024 (InvestorPlace) -5.60%
May-09-24 09:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-03-24 08:02AM	Stifel Starts Phathom Pharmaceuticals With Buy Rating, $24 Price Target (MT Newswires)
Apr-29-24 08:00AM	Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024 (GlobeNewswire)
Apr-22-24 03:30AM	SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT (PR Newswire)
Apr-19-24 03:03PM	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors (Barrons.com) -5.38%
11:02AM	12 Most Shorted Stocks in 2024 (Insider Monkey)
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-03-24 08:00AM	Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
08:00AM	Loading…
Mar-26-24 08:00AM	Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, VOQUEZNA Can Kick Some Acid (GlobeNewswire)
Mar-08-24 03:05PM	Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2023 Earnings Call Transcript (Insider Monkey)
01:57AM	Q4 2023 Phathom Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-24 01:51PM	PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -6.58%
01:38PM	Phathom Pharmaceuticals Inc (PHAT) Reports Q4 and Full Year 2023 Financials, Eyes Growth with ... (GuruFocus.com)
08:00AM	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-29-24 08:00AM	Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024 (GlobeNewswire)
Feb-13-24 08:00AM	Phathom Pharmaceuticals Announces VOQUEZNA (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients (GlobeNewswire)
Jan-31-24 08:00AM	Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Dec-14-23 08:00AM	Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital (GlobeNewswire) +7.98%
Dec-06-23 08:00AM	Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD (GlobeNewswire) -5.36%
Nov-28-23 08:00AM	Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn (GlobeNewswire)
Nov-09-23 09:34AM	Phathom Pharmaceuticals Inc (PHAT) Reports Q3 2023 Financial Results (GuruFocus.com)
08:00AM	Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates (GlobeNewswire)
Nov-01-23 05:00PM	Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults (GlobeNewswire) -16.96%
Oct-30-23 08:00AM	Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA TRIPLE PAK (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA DUAL PAK (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults (GlobeNewswire)
Oct-25-23 08:01AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-26-23 08:01AM	Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD (GlobeNewswire)
Sep-05-23 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.27%
Aug-21-23 08:00AM	Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application (GlobeNewswire)
Aug-10-23 08:01AM	Phathom Pharmaceuticals Reports Second Quarter 2023 Results (GlobeNewswire)
Aug-09-23 10:26AM	UPS downgraded, Eli Lilly upgraded: Wall Street's top analyst calls (The Fly)
Aug-07-23 02:34PM	3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now (InvestorPlace)
Jul-14-23 04:40PM	These 2 Biotech Stocks Are Most Likely to Be Acquired, Says Needham and They Have Over 60% Upside Potential (TipRanks)
Jul-10-23 08:26AM	Zacks.com featured highlights include Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies (Zacks)
Jul-07-23 08:38AM	3 Top Breakout Stocks Worth a Buy for Attractive Returns (Zacks)
06:52AM	Pleasing Signs As A Number Of Insiders Buy Phathom Pharmaceuticals Stock (Simply Wall St.)
Jun-12-23 08:01AM	Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD (GlobeNewswire)
Jun-09-23 04:01PM	Phathom Pharmaceuticals Announces Closing of Underwriters Option to Purchase Additional Shares in Connection with Public Offering of Common Stock (GlobeNewswire) +5.61%
Jun-01-23 09:55AM	Does Phathom Pharmaceuticals, Inc. (PHAT) Have the Potential to Rally 81.38% as Wall Street Analysts Expect? (Zacks)
08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-27-23 09:07AM	Institutional owners may ignore Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) recent US$66m market cap decline as longer-term profits stay in the green (Simply Wall St.)
May-26-23 09:55AM	Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
May-25-23 09:55AM	Should You Buy Phathom Pharmaceuticals, Inc. (PHAT) After Golden Cross? (Zacks)
May-23-23 07:41PM	Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -10.41%
04:01PM	Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:00PM	Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA (GlobeNewswire)
May-10-23 08:00AM	Phathom Pharmaceuticals Reports First Quarter 2023 Results (GlobeNewswire)
May-09-23 08:00AM	Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023 (GlobeNewswire)
Apr-12-23 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.32%
07:07AM	Daily Vickers Top Buyers & Sellers for 04/12/2023 (Argus Research)
Apr-10-23 06:44AM	Daily Vickers Top Buyers & Sellers for 04/10/2023 (Argus Research)
Apr-05-23 08:35AM	Phathom (PHAT) Up 8% on Erosive Esophagitis Drug's CRL Update (Zacks) -9.51%
Apr-04-23 08:00AM	Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch (GlobeNewswire) +8.42%
Mar-27-23 09:55AM	Here's Why Phathom Pharmaceuticals, Inc. (PHAT) Is a Great 'Buy the Bottom' Stock Now (Zacks) +7.92%
Mar-07-23 12:00PM	All You Need to Know About Phathom Pharmaceuticals, Inc. (PHAT) Rating Upgrade to Buy (Zacks) -5.54%
Feb-28-23 08:00AM	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) -11.75%
Feb-10-23 08:53AM	Phathom Pharma Shares Fall After Formal FDA Request For Vonoprazan Data (Benzinga) -29.67%
07:59AM	Phathoms stock falls after receiving FDA letters (MarketWatch)
Feb-09-23 04:01PM	Phathom Pharmaceuticals Provides Regulatory Updates (GlobeNewswire)
Jan-28-23 01:58PM	Why Shares of Phathom Pharmaceutical Jumped This Week (Motley Fool)
Jan-24-23 09:02AM	Great news for Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Insiders acquired stock in large numbers last year (Simply Wall St.) +9.84%
Jan-13-23 06:56AM	Daily Vickers Top Buyers & Sellers for 01/13/2023 (Argus Research) +12.06%
Jan-08-23 06:00PM	Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) (GlobeNewswire)
Jan-06-23 05:02AM	The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax (Zacks)
Jan-05-23 11:31AM	Biotech Stock Roundup: GERN Surges on Study Data, PHAT, VERA Offer Updates & More (Zacks) -6.66%
Jan-04-23 09:17AM	FDA Issues No Action Notice For Phathom Pharma's Investigational Candidate, Shares Plunge (Benzinga) -31.11%
Jan-03-23 04:01PM	Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis (GlobeNewswire) +6.86%
Nov-08-22 05:00PM	Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) -7.55%
Nov-03-22 08:30AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences (GlobeNewswire)
Nov-01-22 08:00AM	Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement (GlobeNewswire)
Oct-24-22 08:00AM	Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD) (GlobeNewswire)
Oct-23-22 12:01PM	Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting (GlobeNewswire)
Oct-18-22 08:00AM	Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting (GlobeNewswire)
Sep-26-22 08:00AM	Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors (GlobeNewswire)
Sep-07-22 08:15AM	Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-17-22 09:16AM	As Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) hits US$444m market cap, insiders may be dismayed about not purchasing higher quantities (Simply Wall St.)
Aug-02-22 08:00AM	Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) -28.78%
Jun-01-22 08:15AM	Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-25-22 08:00AM	Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis (GlobeNewswire) -5.25%

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nabulsi Azmi	Chief Operating Officer	Jul 15 '24	Sale	11.72	10,901	127,760	240,421	Jul 17 02:52 PM
Henderson Molly	CFO and CBO	Jul 15 '24	Sale	11.72	4,325	50,689	99,447	Jul 17 02:51 PM
Curran Terrie	President and Chief Executive	Jul 15 '24	Sale	11.72	33,848	396,699	377,734	Jul 17 02:50 PM
Henderson Molly	CFO and CBO	Apr 08 '24	Sale	11.10	3,435	38,128	95,263	Apr 10 04:30 PM
Curran Terrie	President and Chief Executive	Mar 22 '24	Sale	9.11	16,851	153,513	410,784	Mar 26 04:05 PM
TAKEDA PHARMACEUTICAL CO LTD	10% Owner	Jan 24 '24	Sale	8.10	3,703,703	29,999,994	3,755,583	Jan 25 06:13 AM
Henderson Molly	CFO and CBO	Jan 19 '24	Sale	7.75	6,307	48,900	98,698	Jan 22 08:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PHAT

Phathom Pharmaceuticals Inc

Upgrade your FINVIZ experience